aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Fan, R; Papatheodoridis, G; Sun, J; Innes, H; Toyoda, H; Xie, Q; Mo, S; Sypsa, V; Guha, IN; Kumada, T; Niu, J; Dalekos, G; Yasuda, S; Barnes, E; Lian, J; Suri, V; Idilman, R; Barclay, ST; Dou, X; Berg, T; Hayes, PC; Flaherty, JF; Zhou, Y; Zhang, Z; Buti, M; Hutchinson, SJ; Guo, Y; Calleja, JL; Lin, L; Zhao, L; Chen, Y; Janssen, HLA; Zhu, C; Shi, L; Tang, X; Gaggar, A; Wei, L; Jia, J; Irving, WL; Johnson, PJ; Lampertico, P; Hou, J

Journal article

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Abstract:: Background & Aims
Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.

Methods
A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686).

Results
We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin–bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82–0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0–0.8%, 1.5–4.8%, and 8.1–19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7–100% and a negative predictive value of 99.3–100%. The cut-off value of 60 resulted in a specificity of 56.6–95.8% and a positive predictive value of 6.6–15.7%.

Conclusions
This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa, V., Guha, I. N., Kumada, T., Niu, J., Dalekos, G., Yasuda, S., Barnes, E., Lian, J., Suri, V., Idilman, R., Barclay, S. T., Dou, X., … Hou, J. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 73(6), 1368–1378.

MLA Style

Fan, R., et al. “AMAP Risk Score Predicts Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis.” Journal of Hepatology, vol. 73, no. 6, Elsevier, 2020, pp. 1368–78.

Chicago Style

Fan, R, G Papatheodoridis, J Sun, H Innes, H Toyoda, Q Xie, S Mo, et al. 2020. “AMAP Risk Score Predicts Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis.” Journal of Hepatology 73 (6): 1368–78.
Share
Print